Understanding how prostate cancer responds to B7-H3 targeted treatments
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)
This study is looking at why some men with prostate cancer, who haven't responded to regular treatments, might benefit from new therapies that target a protein called B7-H3, using advanced techniques to understand how their cancer cells behave.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11061222 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the sensitivity of prostate cancer to therapies that target the B7-H3 protein. It focuses on patients who have developed resistance to standard androgen receptor-targeting treatments. By examining the role of specific transcription factors and regulatory sites that influence B7-H3 expression, the study aims to uncover why some patients benefit from B7-H3 therapies. The research employs advanced techniques like single-cell RNA sequencing to analyze tumor cells and their responses to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are prostate cancer patients who have shown resistance to androgen receptor-targeting therapies.
Not a fit: Patients with early-stage prostate cancer who have not undergone androgen receptor-targeting treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for prostate cancer patients who have become resistant to current therapies.
How similar studies have performed: Previous studies have shown promising results with B7-H3 targeted therapies in prostate cancer, indicating potential for success in this research.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Hwang, Justin H. — University of Minnesota
- Study coordinator: Hwang, Justin H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.